![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 23, 17894-17899, June 9, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the University of California, San Francisco, School of
Medicine, Cancer Research Institute,
San Francisco, California 94115
Received for publication, July 8, 1999, and in revised form, February 28, 2000
Wnt signaling involves inhibition of glycogen
synthase kinase-3 Lithium has marked effects on the embryonic development and patterning
in different organisms including Xenopus and
Dictyostelium (31). In Xenopus embryos, lithium
causes axis duplication, resembling a phenotype caused by
overexpression of Wnt, dominant negative GSK-3 Normally, GSK-3 Here we provide evidence that growth factors can enhance
lithium-induced Materials--
EGF, calphostin C, GF-109203X
(bisindolylmaleimide I), and TPA
(12-O-tetradecanoylphorbol-13-acetate) were obtained from
Calbiochem. Insulin, platelet-derived growth factor, insulin-like
growth factor-1, and L- Cellular Fractionation, Electrophoresis, and
Immunoblotting--
Cytoplasmic and membrane fractions were prepared
according to a protocol described previously (56). Briefly, cells were washed twice and scraped in phosphate-buffered saline and the cell
pellets were resuspended in ice-cold hypotonic buffer (20 mM Tris, pH 7.5, 25 mM sodium fluoride, and 1 mM EDTA) containing a protease inhibitor mixture tablet
(Roche Molecular Biochemicals). Cells were lysed by incubating on ice
for 20 min, followed by 30 strokes in a Dounce homogenizer. The lysates
were subject to ultracentrifugation at 100,000 × g for
30 min at 4 °C. The supernatant and the pellet were collected as the
cytoplasmic fraction (S100 fraction) and the membrane fraction (P100
fraction), respectively. Protein concentration of the cytoplasmic
extracts was estimated by using Bradford reagent (Bio-Rad). Equal
amounts of protein from each lysate was analyzed by 10 or 7.5%
SDS-polyacrylamide gel electrophoresis. The protein bands were
transferred to polyvinylidene difluoride membranes (Millipore), blocked
in 2% bovine serum albumin, 1× TBS, 0.05% Tween 20. Membranes were
incubated with appropriate primary antibodies for 1 h at room
temperature or overnight at 4 °C and then probed with horseradish
peroxidase-conjugated secondary antibodies. ECL reagents (Amersham
Pharmacia Biotech) were used to visualize the protein bands on the
membranes, Semi-Quantitation by Gel Doc 1000 (Bio-Rad).
Transfections and Luciferase Assay--
Transfections were
performed by using LipofectAMINE (Life Technologies, Inc.) or FuGENE 6 (Roche Molecular Biochemicals) according to the manufactures
instructions. Cells from one 10-cm dish were transfected with 5 µg of
the TOPFlash reporter plasmid or 5 µg of activator plasmids plus 2.5 µg of the TOPFlash reporter plasmid. Ten hours after transfection,
the cells were split into eight 6-well dishes. Cells were serum-starved
overnight, followed by stimulation with different stimuli for another
16 h. Cells were washed once with phosphate-buffered saline and
then lysed for 15 min at room temperature. The lysates were clarified
by centrifugation at 14,000 rpm for 10 min and 20 µl of each lysate
was used to measure luciferase reporter gene expression (luciferase
assay kit, Promega). The luciferase activity was either normalized to Renilla luciferase activity from co-transfected internal
control plasmid pRL-TK or normalized to protein concentration. All
experiments were performed in duplicate at least 3 times.
Establishment of Stable C57MG-V12 Cell Line by Retroviral
Infections--
Each 6-cm dish was seeded with 2 × 105 C57MG cells the day before infection. The medium was
removed from the dishes, and the virus stocks and Polybrene (final
concentration of 8 µg/ml) (Sigma) were added to the cells and
incubated for at least 5 h. Cells were allowed to recover in fresh
media for 24 h before being split into G418 containing media for
selection. After 2 weeks of selection, cells that are resistant to G418
were pooled together for further analysis.
Serum Stimulates Accumulation of Cytoplasmic Growth Factors Activate the Wnt/ Serum Effect on Cytoplasmic Levels of
Ras is a major mediator in the growth factor signaling pathways (60,
61). We wondered if Ras might be involved in synergizing with lithium
in PKC Is Necessary for Serum Potentiation of Lithium-induced
TPA-sensitive PKCs Are Necessary But Not Sufficient for the Full
Accumulation of
PKC has been shown to participate in the inactivation of GSK-3 From genetic and biochemical studies of Drosophila and
Xenopus, a linear pathway has been elucidated from the
extracellular ligand Wnt to the transcription factor Tcf/Lef. Wnt binds
to its receptor Frizzled, triggering the activation of Dishevelled,
which in turn leads to the inactivation of GSK-3 It is interesting that Wnt-1 and growth factors inactivate GSK-3 Lithium has profound effects on morphogenesis in diverse organisms
(31). One action of lithium has been recently shown to mimic Wnt
signaling by direct inhibition of GSK-3 Which serum-activated pathways are involved in the cooperation with
lithium to induce cytoplasmic The role of PKC in the Wnt signaling pathway remains controversial.
In vitro, PKC has been shown to phosphorylate and inactivate GSK-3 (51). An earlier report showed that a PKC inhibitor Ro31-8220 or
chronic treatment with TPA resulted in complete block of Wnt-mediated inhibition of GSK-3 The importance of PKCs in colon cancer has been demonstrated in
transgenic PKC We thank Dr. P. Polakis, Dr. H. Clevers, Dr.
A. Brown, Dr. P. Parker, Dr. P. Rodriguez-Viciana, and Dr. H. Jiang for
plasmids, retroviruses, and cell lines. We thank Dr. D. Stokoe and Dr.
P. Sabbatini for critical reading of the manuscript. We also thank members of Dr. Frank McCormick's laboratory for discussions and help.
*
This work was supported in part by the Daiichi Cancer
Research Program.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: University of
California, San Francisco, School of Medicine, Cancer Research
Institute, 2340 Sutter Street, San Francisco, CA 94115. Tel.:
415-502-1710; Fax: 415-502-3179; E-mail: mccormick@cc.ucsf.edu.
Published, JBC Papers in Press, April 3, 2000, DOI 10.1074/jbc.M905336199
The abbreviations used are:
GSK-3
Wnt Signaling to
-Catenin Involves Two Interactive
Components
GLYCOGEN SYNTHASE KINASE-3
INHIBITION AND ACTIVATION OF
PROTEIN KINASE C*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(GSK-3
) and elevation of cytoplasmic
-catenin. This pathway is essential during embryonic development and
oncogenesis. Previous studies on both Xenopus and mammalian
cells indicate that lithium mimics Wnt signaling by inactivating
GSK-3
. Here we show that serum enhances accumulation of cytoplasmic
-catenin induced by lithium in both 293 and C57MG cell lines and
that growth factors are responsible for this enhancing activity. Growth
factors mediate this effect through activation of protein kinase C
(PKC), not through Ras or phosphatidylinositol 3-kinase. In addition,
Wnt-induced accumulation of cytoplasmic
-catenin is partially
inhibited by PKC inhibitors and by chronic treatment of cells with
phorbol ester. Both calphostin C, a PKC inhibitor, and a dominant
negative PKC exhibit partial inhibition on Wnt-mediated transcriptional activation. We therefore propose that Wnt signaling to
-catenin consists of two interactive components: one involves inhibition of
GSK-3
and is mimicked by lithium, and the other involves PKC and
serves to augment the effects of GSK-3
inhibition.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Catenin was originally identified as a cytoplasmic protein
that binds to the cell adhesion molecule cadherin in cell-cell junctions where it connects cadherin to the actin cytoskeleton (1-3).
It is also involved in the Wnt signaling pathway to regulate developmental processes in a variety of organisms, and in tumorigenesis (4-6). In normal or non-stimulated cells, the majority of the
-catenin protein is present in cell-cell junctions with very little
in cytoplasmic or nuclear fractions. This is due to rapid turnover of
-catenin promoted by complexes containing the adenomatous polyposis
coli protein, GSK-3
,1 and
Axin/Conductin (7-14). The N-terminal clusters of serine and threonine
residues of
-catenin are putative GSK-3
phosphorylation sites
(8), which serve as signals for ubiquitin-mediated degradation (15-17). Recently, an F-box protein
-TrCP in a ubiquitin-ligase complex has been shown to be involved in the proteasome-mediated degradation of phosphorylated
-catenin (18-20). However, in the presence of a Wnt signal, a Frizzled family receptor and the downstream component Dishevelled are activated. Dishevelled in turn leads to the
inactivation of GSK-3
, causing the accumulation of cytoplasmic
-catenin. High levels of
-catenin in the cytosol result in its translocation into the nucleus and subsequent interaction with the
Tcf/Lef family of transcription factors to activate expression of
Wnt-responsive genes (6). Recently, c-myc and cyclin
D1 have been identified as target genes of
-catenin (21, 22). In colon cancer cells, adenomatous polyposis coli protein is frequently mutated resulting in elevated levels of cytoplasmic
-catenin (23).
In addition,
-catenin mutations have been detected in colon cancer
cell lines with wild-type adenomatous polyposis coli protein and other
types of cancer (24-28). The majority of these mutations are located
in the putative GSK-3
phosphorylation sites (29, 30). Similarly,
these mutations result in stabilization of the
-catenin protein.
Intracellular levels of
-catenin are therefore regulated by
different signaling pathways and play a central role in both
development and tumorigenesis.
, or
-catenin
(32-35). In Dictyostelium, lithium alters cell fate
determination, resulting in transformation of pre-spore cells into
pre-stalk cells (36). In isolated rat adipocytes, treatment with
lithium leads to increased glycogen synthesis (37). The action of
lithium has been previously attributed to depletion of inositol, based
on the observation that lithium inhibits inositol monophosphatase (38).
However, recent observations suggest that lithium may mimic Wnt
signaling by direct inhibition of GSK-3
, leading to the accumulation
of cytoplasmic
-catenin (39-41). This is consistent with the fact
that GSK-3
is a highly conserved serine/threonine protein kinase in
evolution and plays a central role in diverse biological processes
including those affected by lithium (34, 42-48).
is highly active in resting cells. However, many
extracellular stimuli result in the inhibition of its activity. For
example, stimulation by insulin and growth factors activates the
phosphatidylinositol 3-kinase (PI3K) pathway and the subsequent protein
kinase B (PKB) activation leads to inhibition of GSK-3
, probably via
the N-terminal Ser-9 phosphorylation (49). Interestingly, Wnt
stimulation also leads to similar degrees of inhibition of GSK-3
yet
does not involve PI3K pathway, p70 S6 kinase, or MAP kinase pathway
(50). Instead, TPA-sensitive isoforms of protein kinase C (PKC) have
been shown to be involved in Wnt-induced inactivation of GSK-3
(50).
PKC has been shown to phosphorylate and inactivate GSK-3
in
vitro (51). However, the role of PKC activation in Wnt-induced
-catenin accumulation remains unknown. Inactivation of GSK-3
by
Wnt causes slower cytoplasmic turnover and increased nuclear
translocation of
-catenin, and leads to activation of Wnt target
gene expression. However, there is no evidence that GSK-3
inhibition
by insulin or growth factor stimulation leads to
-catenin
accumulation and Tcf/Lef-dependent transcriptional activation.
-catenin accumulation and transactivation.
This enhancement is through a distinct signaling pathway that
involves TPA-sensitive isoforms of PKC. More importantly, our study
suggests that two different components, one mimicked by lithium and the other mediated by PKC, contribute to Wnt-induced
-catenin
stablization and activation of gene expression.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-lysophosphatidic acid (oleoyl)
were purchased from Sigma. The monoclonal antibodies against
-catenin and actin were purchased from Transduction Laboratories and
Amersham Pharmacia Biotech, respectively. C57MG, C57MG-MV, C57MG-Wnt-1,
Rat2-MV, and Rat2-Wnt-1 cell lines were generous gifts from Dr. Anthony
Brown (Cornell University Medical College, New York) (52, 53).
Conditioned Wnt media were made as described previously (67). 293-Wnt-1 cells were made from the pLNCX-Wnt-1 plasmid generously provided by Dr. Roel Nusse (Stanford University, CA). p110-CAAX,
gag-PKB mammalian expression plasmids, and packaging cell lines for
vector and RasVal-12 retroviruses were kindly provided by
Dr. Pablo Rodriguez-Viciana. TOPFlash (a reporter plasmid containing
multiple copies of wild-type Tcf-binding sites), FOPFlash (a reporter
plasmid containing mutant Tcf-binding sites), full-length human Tcf4,
and dominant negative Tcf4 were generous gifts from Dr. Hans Clevers
(Utrecht University, The Netherlands) (54). PKC
(T/A)3, a
dominant negative form of PKC
(DN-PKC), was a gift from Dr. Peter
Parker (Imperial Cancer Research Fund, United Kingdom) (55).
AP-1-luciferase (AP-1-Luc) and p53-luciferase (p53-Luc) reporter
plasmids were purchased from Stratagene. Cells were maintained in
Dulbecco's modified Eagle's medium with 10% fetal calf serum and 1%
penicillin/streptomycin. 1 mg/ml G418 (Life Technologies, Inc.) was
added where selection was necessary.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Catenin in the
Presence of Lithium--
Regulation of cytoplasmic
-catenin is
critical for its signaling function. In colon carcinomas, cytoplasmic
-catenin levels and Tcf/Lef-dependent transcription can
be up-regulated by either the loss of adenomatous polyposis coli
protein function or mutations of the putative GSK-3
phosphorylation
sites in the N-terminal region of
-catenin (27, 29, 30). Wnt
stimulation also specifically causes repression of GSK-3
activity
and subsequent
-catenin accumulation in the cytosol and nucleus (6).
We asked whether serum stimulation, which has been shown to decrease
GSK-3
activity to a similar extent as Wnt stimulation (50, 57),
would induce cytoplasmic
-catenin accumulation. To test this
possibility, cells were stimulated with serum, lysed in hypotonic
buffer, and fractionated by ultracentrifugation. Normalized amounts of
S100 lysates were separated by 10% SDS-polyacrylamide gel
electrophoresis and cytoplasmic
-catenin was visualized by
immunoblotting. As shown in Fig.
1A, serum stimulation alone
did not lead to cytoplasmic accumulation of
-catenin. However,
lithium did increase cytoplasmic
-catenin levels, which is
consistent with previous observations that lithium acts as a
non-competitive inhibitor of GSK-3
and leads to the cytoplasmic
accumulation of
-catenin (39-41). Surprisingly, when cells were
stimulated with both serum and lithium, a much more pronounced
accumulation of cytoplasmic
-catenin in C57MG and 293 cells was
observed (Fig. 1A and data not shown). Furthermore, serum
and lithium also synergistically enhanced transcriptional activation of
a reporter gene with multiple copies of Tcf-binding sites (TOPFlash)
(Fig. 1B). Whereas lithium activated the reporter gene only
up to 3-fold, lithium plus serum gave rise to 10-fold activation in 293 cells. These results indicate that serum by itself does not have a
significant effect on
-catenin levels, yet can potentiate the effect
of lithium on cytoplasmic
-catenin accumulation and
-catenin-dependent transcriptional activation.

View larger version (14K):
[in a new window]
Fig. 1.
Serum enhancement of lithium-induced
cytoplasmic
-catenin accumulation and
-catenin dependent transactivation.
A, C57MG mammary epithelial cells were starved for 24 h, followed by stimulation with 10 mM lithium, 20% fetal
bovine serum, and lithium plus serum for 3 h. Cells were then
lysed and fractionated into S100 fractions. Equivalent amounts of
protein from each S100 cytosolic fraction were analyzed by
immunoblotting with a monoclonal antibody against
-catenin.
Quantified representation of the Western blot is shown as percentage of
maximum at the bottom (Relative intensity).
B, 293 cells were transiently transfected with the Tcf
reporter plasmid (TOPFlash) and serum-starved for 16-24 h, and then
stimulated with the indicated stimuli for another 16 h. Cell
lysates, normalized to equal protein concentrations, were assayed for
luciferase activity. The results are plotted as a percentage of maximum
activity. Averages of three independent transfections are shown and the
standard deviations are less than 10%.
-Catenin Signal Transduction
Pathway in the Presence of Lithium--
In order to find out what is
responsible for the serum enhancement of lithium-induced
-catenin
stablization, we used L-
-lysophosphatidic acid and
different growth factors, instead of serum, to stimulate cells.
L-
-Lysophosphatidic acid neither caused the accumulation of
-catenin by itself nor had any synergistic effect with lithium (data not shown). Combinations of growth factors (insulin,
platelet-derived growth factor, insulin-like growth factor-1, and EGF)
could substitute for serum stimulation (Fig.
2A). Among them, EGF partially
substituted serum in
-catenin accumulation (data not shown) and
-catenin-dependent transcriptional activation (Fig.
2B). Therefore, growth factors play a major role in the
cooperation of serum with lithium on the cytoplasmic
-catenin
stablization and
-catenin-dependent transcriptional
activation.

View larger version (17K):
[in a new window]
Fig. 2.
Growth factors are responsible for
cooperation with lithium in
-catenin
accumulation and transcriptional activation. A,
combination of growth factors (GFs) (50 ng/ml EGF, 50 ng/ml
platelet-derived growth factor, 50 ng/ml insulin-like growth factor-1,
and 500 ng/ml insulin) was used to stimulate serum-starved 293 cells
with or without 10 mM lithium. Cytosolic fractions were
analyzed by immunoblotting with monoclonal antibodies against
-catenin and actin. Normalized quantification of the Western blots
is shown as percentage of maximum at the bottom (Relative
ratio). B, EGF enhances lithium-induced
-catenin-dependent transcriptional activation. Plasmid
transfections and reporter gene assays were performed as described in
the legend to Fig. 1. Cells were stimulated with EGF (50 ng/ml),
lithium (10 mM), or with combination of EGF and lithium for
16 h. Relative luciferase activity is shown as a percentage of
maximum activity.
-Catenin Does Not Involve
PI3K and Ras--
Since growth factors contributed to the serum effect
on
-catenin accumulation, we reasoned that growth factors might
elicit their functions by feeding into GSK-3
via PI3K/PKB pathway
(49, 58). Therefore, we examined if a constitutively active form of
PI3K (p110-CAAX) (59) would substitute for serum in the reporter gene
assay described earlier. p110-CAAX, co-transfected with the reporter
TOPFlash, neither activated the reporter gene by itself nor synergized
with lithium. Moreover, lithium-induced reporter gene activity could be
further increased by serum stimulation in the p110-CAAX-transfected 293 cells (Fig. 3A). Likewise,
co-transfection of gag-PKB, an activated form of PKB, with TOPFlash
failed to enhance lithium-induced reporter gene activation (data not
shown).

View larger version (21K):
[in a new window]
Fig. 3.
Neither PI3K nor Ras is involved in mediating
serum enhancement of
-catenin accumulation and
transcriptional activation. A, 293 cells in 10-cm
dishes were co-transfected with 5 µg of either pcDNA3 or
p110-CAAX (a constitutively active form of PI3K) and 2.5 µg of the
TOPFlash plasmid. The cells were then split into eight 6-well dishes,
serum-starved, and stimulated as indicated for 16 h. Reporter gene
activities were assayed and shown as percentages of maximum activity.
B, accumulation of cytoplasmic
-catenin in C57MG-Vector
and C57MG-V12 cells. C57MG cells were infected with vector or
RasVal-12 retroviruses and selected with 1 mg/ml G418 for
1-2 weeks. The G418-resistant cells were pooled and analyzed for
cytoplasmic
-catenin levels in response to serum, lithium, or both
by immunoblotting.
-catenin accumulation. We made a stable C57MG-V12 cell line
expressing activated RasVal-12. The C57MG-V12 cells showed
typical morphology of Ras-transformed cells (data not shown). We then
examined if RasVal-12 could substitute for serum in
potentiation of
-catenin accumulation by lithium. The C57MG-V12
cells did not accumulate more cytoplasmic
-catenin than the vector
cells when treated with lithium. In addition, the cytoplasmic
-catenin levels in both the vector and the C57MG-V12 cells could be
further elevated to a similar extent by treatment with serum and
lithium (Fig. 3B). Therefore, expression of
RasVal-12 cannot substitute for serum in potentiation of
-catenin accumulation.
-Catenin Accumulation--
One of the other candidate pathways
activated by serum and growth factors is the PKC pathway. To
investigate if PKC is involved in the accumulation of
-catenin, we
tested TPA, a potent activator of certain isoforms of PKC, in
conjunction with lithium to induce
-catenin accumulation. TPA alone
had little effect on the cytoplasmic
-catenin levels. Interestingly,
TPA plus lithium stimulated further the accumulation of
-catenin
(Fig. 4A). The level of
stimulation by TPA is comparable to that of serum. These results
suggest that although activation of PKC alone is not sufficient for
activation of Wnt signaling pathway, it can enhance Wnt signaling by
cooperating with lithium. We postulated that the serum cooperation
might be due to the activation of PKC. To test this, we pretreated
cells with calphostin C, a PKC inhibitor, before being stimulated with serum and lithium. As shown in Fig. 4B, treatment of
calphostin C inhibited serum potentiation of
-catenin accumulation.
Furthermore, long-term treatment of cells with TPA ablated the serum
potentiation of lithium-stimulated
-catenin accumulation (data not
shown). Chronic treatment of cells with TPA has been shown to
down-regulate the TPA-sensitive isoforms of PKC. Therefore, the
TPA-sensitive isoforms of PKC might be responsible for the enhancement
of lithium-induced
-catenin accumulation by serum.

View larger version (18K):
[in a new window]
Fig. 4.
PKC contributes to the serum enhancement of
lithium-induced
-catenin accumulation.
A, TPA enhances lithium-induced
-catenin accumulation.
293 cells were serum-starved for 24 h and then stimulated with 100 ng/ml TPA, 10 mM lithium or both. Cytoplasmic
-catenin
levels were analyzed as described. B, calphostin C inhibits
the serum enhancement of lithium-induced
-catenin accumulation.
Serum-starved 293 cells were pretreated with calphostin C (1 µM) for 30 min before stimulation. Cytoplasmic fractions
were analyzed for
-catenin and actin levels. Normalized
quantification of the Western blots is shown at the bottom
of each panel.
-Catenin Induced by Wnt-1--
Wnt signaling also
leads to cytoplasmic
-catenin accumulation by inhibiting GSK-3
activity (62, 63). Since lithium mimics the Wnt signaling in terms of
inhibiting the activity of GSK-3
, we examined if serum could also
enhance the Wnt signaling by increasing Wnt-stimulated
-catenin
accumulation. C57MG-Wnt-1 cells showed elevated levels of cytoplasmic
-catenin (52, 53). However, serum starvation or serum stimulation of
C57MG-Wnt-1 cells did not affect the levels of cytoplasmic
-catenin
accumulation (Fig. 5A).
Therefore, serum does not seem to further enhance
-catenin accumulation induced by Wnt-1 expression. This observation suggests that lithium is not the surrogate for the Wnt signaling, and serum or
growth factors can provide additional signal(s) that leads to further
accumulation of
-catenin.

View larger version (31K):
[in a new window]
Fig. 5.
PKC is necessary for full activation of
Wnt/
-catenin pathway. A, Wnt-1
activates
-catenin accumulation in the absence of serum. C57MG-MV
(vector) and C57MG-Wnt-1 cells were starved or restimulated with 20%
fetal calf serum. Cytoplasmic fractions were analyzed for
-catenin
accumulation. B, calphostin C partially inhibits
-catenin
accumulation in the C57MG-Wnt-1 cells. The C57MG-MV or C57MG-Wnt-1
cells were treated with increasing concentrations of calphostin C (0.2 µM to 1 µM) for 3 h, harvested,
fractionated, and analyzed for cytoplasmic
-catenin levels.
C, chronic treatment of C57MG cells with TPA partially
blocks their responses to conditioned Wnt-1 media. C57MG cells were
treated with dimethyl sulfoxide, TPA at 0.2, 1, or 5 µM
for 24 h. The cells were then stimulated with either control or
Wnt-1 media for 3 h. Cytoplasmic fractions were analyzed for
-catenin and actin levels. Normalized quantification is shown at the
bottom of panels B and C.
by
Wnt (50). To investigate whether PKC is involved in the
-catenin
accumulation induced by Wnt-1, we treated the Wnt-1 cells with
different PKC inhibitors and examined the cytoplasmic
-catenin
accumulation by immunoblotting. Treatment of the C57MG-Wnt-1 or
293-Wnt-1 cells with increasing concentrations of calphostin C for
3 h resulted in gradual reduction of the cytoplasmic
-catenin (Fig. 5B and data not shown). Similarly, chronic treatment
of C57MG-Wnt-1 or 293-Wnt-1 cells with TPA or treatment of the
C57MG-Wnt-1 cells with GF-109203X (1 µM) also led to
partial inhibition of
-catenin accumulation (data not shown).
Furthermore,
-catenin accumulation stimulated by conditioned Wnt
media was also partially inhibited by treatment of calphostin C, as
well as by chronic treatment of TPA in C57MG and 293 cells (Fig.
5C and data not shown). To test whether the inhibition of
-catenin accumulation by these inhibitors has any functional
significance, we assayed the Tcf reporter activity in 293-Wnt-1 cells.
The reporter activity was 10-fold higher in 293-Wnt-1 cells compared
with 293-Vector cells and was partially inhibited by calphostin C in a
dose-dependent manner in 293-Wnt-1 cells (Fig.
6A). To further strengthen the conclusion from the PKC inhibitor experiments, we employed
PKC
(T/A)3, a dominant negative PKC (DN-PKC), to test
whether it has any effect on Wnt-mediated transcriptional activation.
In control experiments, DN-PKC blocked 70% of TPA-stimulated AP-1
luciferase reporoter activity (Fig. 6B, left panel) and it
had no significant effect on p53-mediated transcriptional activation
(Fig. 6B, right panel). The expression of DN-PKC caused
partial loss of Wnt-induced transcriptional activation in a
dose-dependent manner, although it was not as strong as the
dominant negative Tcf4 (DN-Tcf4) (Fig. 6B, middle panel).
Since activation of PKC by TPA alone did not result in any accumulation
of cytoplasmic
-catenin, we conclude that activation of PKC is not
sufficient for transduction of Wnt signal yet it is an important
component of Wnt signaling.

View larger version (31K):
[in a new window]
Fig. 6.
PKC participates in Wnt-mediated activation
of transcription. A, calphostin C partially inhibits
Wnt-associated transcriptional activation. 293-Wnt-1 or 293-Vector
cells were transfected with the reporter plasmid TOPFlash and the
internal control plasmid pRL-TK for 24 h. Cells were treated with
increasing concentrations of calphostin C (0.1 to 1 µM)
for another 16 h and then harvested for luciferase assay. The
activity is expressed as a percentage of maximum luciferase activity.
B, in 12 wells, 293-Wnt-1 cells were co-transfected with 0.2 µg of each reporter plasmid (AP-1-Luc, TOPFlash, or p53-Luc) and 1 µg of the dominant negative PKC (DN-PKC). For AP-1
luciferase assay, the cells were stimulated with 200 ng/ml TPA for
16 h; for TOPFlash luciferase assay, 0.5 or 1 µg of DN-PKC or
the dominant negative Tcf4 (DN-Tcf4) was co-transfected; for p53
luciferase assay, 0.3 µg of p53 was used as an activator. The
luciferase activity is expressed as a percentage of the maximum
activity in each assay and represents the average of triplicates of
three independent experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(6). Inactivation of GSK-3
abolishes the phosphorylation and ubiquitin-mediated degradation of
-catenin (18-20). Nevertheless, the molecular
mechanisms underlying the inactivation of GSK-3
and
-catenin
accumulation have not been fully understood. It has been proposed that
PKC might be involved in the inactivation of GSK-3
because certain inhibitors of PKC are capable of antagonizing Wnt-mediated GSK-3
inactivation (50). Our data further demonstrated that Wnt/
-catenin pathway could comprise two components, one is mimicked by lithium and
the other involves PKC.
to
a similar extent (50, 57), yet only Wnt-1 can induce cytoplasmic
-catenin accumulation (Figs. 1 and 5). Earlier studies have
indicated that signaling from growth factors (e.g. insulin) to GSK-3
is wortmannin sensitive and involves PKB (49, 64, 65)
whereas that from Wnt to GSK-3
is insensitive to wortmannin treatment (50). Instead, Wnt-1-induced GSK-3
inactivation is completely blocked by certain PKC inhibitors (50). Therefore, the
pathway from GSK-3
inhibition to cytoplasmic
-catenin
accumulation appears to be fundamentally different between Wnt
signaling and growth factor signaling. In the case of insulin
signaling, GSK-3
inhibition is mediated by phosphorylation of Ser-9
on GSK-3
(66-68); in Wnt signaling, GSK-3
activity is inhibited
to 50% of its normal activity but little is known about the mechanism
of the inhibition. It is of interest to study whether Wnt-mediated
GSK-3
inhibition is accomplished via covalent modification and
whether different pools of GSK-3
are involved in Wnt signaling.
causing the accumulation of
cytoplasmic
-catenin (39-41). In this study, we confirmed the
lithium effect on GSK-3
inhibition (data not shown) and
-catenin
accumulation in both 293 and C57MG cells. We further showed that serum
or growth factors could cooperate with lithium to induce
-catenin
stablization (Figs. 1 and 2). This raised a possibility that Wnt might
also synergize with serum or growth factors to induce maximum
accumulation of
-catenin. However, our results indicated that
Wnt-induced
-catenin accumulation is independent of serum (Fig. 5).
These observations imply that lithium might only partially mimic the
Wnt signaling pathway.
-catenin accumulation? We ruled out
the involvement of PI3K/PKB and Ras in the synergistic stablization of
-catenin (Fig. 3). Since PKC is implicated as a candidate component
in the Wnt signal transduction, we examined PKC inhibitors on serum
enhancement of lithium-induced
-catenin accumulation. Indeed, PKC
inhibitors completely block the serum enhancement function. The role of
PKC is further supported by the observation that TPA, a potent
activator of certain PKC isoforms, can also cooperate with lithium
(Fig. 4). In conclusion, we identified a pathway involving PKC that
enhances lithium-induced
-catenin accumulation. It is noteworthy
that a synergy between lithium and insulin-like growth factor-1 is
reported in the stimulation of granule neuron progenitor proliferation,
a process involving inhibition of GSK-3
(69). Questions emerge as
what is the target(s) of growth factors/PKC pathway. One possibility is
that growth factors/PKC may cooperate with lithium in the inactivation
of GSK-3
. To test this hypothesis, we immunoprecipitated GSK-3
kinase from resting cells or serum-stimulated cells and performed in vitro kinase assay in the presence of increasing amounts
of lithium. We did not observe any cooperative inhibition of GSK-3
by serum and lithium (data not shown). However, considering the nature
of the in vitro kinase assay, we still cannot rule out the
possibility of cooperative inhibition of GSK-3
by serum and lithium
in vivo. Further study is needed to dissect the converging point from activation of PKC to
-catenin accumulation.
in mouse 10T1/2 fibroblasts (50). In that study,
the authors did not determine the effect of these PKC inhibitors on
Wnt-induced
-catenin accumulation. On the other hand, others reported that treatment with the PKC inhibitors GF-109203X or Ro31-8220
caused
-catenin accumulation in certain human breast epithelial cell
lines, whereas treatment with the PKC inhibitor calphostin C or
TPA-induced down-regulation of PKCs has no significant effect on
-catenin accumulation (15). Our data showed that Wnt-dependent
-catenin stablization was partially
inhibited by certain PKC inhibitors (Fig. 5 and data not shown). The
discrepancy may be explained by the differences of these inhibitors on
various isoforms of PKCs or their nonspecific effects on other kinases. It is possible that TPA-sensitive PKCs are involved in the Wnt-induced GSK-3
inactivation whereas atypical PKCs contribute to
-catenin degradation (15, 50). However, the most plausible explanation is from
the recent publication by Hers and colleagues (70), who showed that the
PKC inhibitors GF-109203X and Ro31-8220 also inhibit GSK-3
,
potentially slowing down
-catenin degradation.
II mice that exhibit hyperproliferation
and increased Wnt signaling in the colonic epithelium (71). Recently, certain Wnt and Frizzled homologs have been reported to modulate PKC
but have no effect on expression of
-catenin target genes, whereas
other Frizzled homologs capable of activating
-catenin target genes
do not activate PKC (72). Consistent with the report, we found that
molecules such as growth factors or TPA that activate PKCs do not
stimulate any detectable
-catenin accumulation and transcriptional
activation. In contrast, using inhibitors and the dominant negative PKC
mutant, we showed that PKCs do participate in Wnt/
-catenin
signaling, although they are not the essential components of this
pathway. For example, calphostin C-mediated PKC inhibition or
TPA-induced PKC down-regulation results in partial inhibition of
Wnt-induced
-catenin accumulation. Furthermore, both calphostin C
and the dominant negative PKC inhibit partially the Wnt-mediated
Tcf/Lef reporter activation. These results strengthened the notion that
PKC activation alone is not sufficient to cause stablization of
-catenin, but it is a component of Wnt pathway that leads to maximum
accumulation of
-catenin and transcriptional activation. Elevation
of
-catenin levels in the cytosol and nucleus as well as its
transcriptional activity is strongly correlated with tumorigenesis.
Therefore, understanding the regulation of free
-catenin pools by
different signaling pathways could facilitate the development of new
strategies to regulate
-catenin signaling.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Recipient of the Carol Franc Buck Fellowship of the Cancer
Research Institute at University of California, San Francisco.
![]()
ABBREVIATIONS
, glycogen
synthase kinase-3
;
PKB, protein kinase B;
PI3K, phosphatidylinositol
3-kinase;
TPA, 12-O-tetradecanoylphorbol-13-acetate;
PKC, protein kinase C;
EGF, epidermal growth factor;
DN, dominant
negative.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kemler, R.
(1993)
Trends Genet.
9,
317-321
2.
Aberle, H.,
Schwartz, H.,
and Kemler, R.
(1996)
J. Cell. Biochem.
61,
514-523
3.
Gumbiner, B. M.
(1996)
Cell
84,
345-357
4.
Polakis, P.
(1999)
Curr. Opin. Genet. Dev.
9,
15-21
5.
Eastman, Q.,
and Grosschedl, R.
(1999)
Curr. Opin. Cell Biol.
11,
233-240
6.
Cadigan, K. M.,
and Nusse, R.
(1997)
Genes Dev.
11,
3286-3305
7.
Munemitsu, S.,
Albert, I.,
Souza, B.,
Rubinfeld, B.,
and Polakis, P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
3046-3050
8.
Rubinfeld, B.,
Albert, I.,
Porfiri, E.,
Fiol, C.,
Munemitsu, S.,
and Polakis, P.
(1996)
Science
272,
1023-1026
9.
Behrens, J.,
Jerchow, B. A.,
Wurtele, M.,
Grimm, J.,
Asbrand, C.,
Wirtz, R.,
Kuhl, M.,
Wedlich, D.,
and Birchmeier, W.
(1998)
Science
280,
596-599
10.
Hart, M. J.,
de los Santos, R.,
Albert, I. N.,
Rubinfeld, B.,
and Polakis, P.
(1998)
Curr. Biol.
8,
573-581
11.
Ikeda, S.,
Kishida, S.,
Yamamoto, H.,
Murai, H.,
Koyama, S.,
and Kikuchi, A.
(1998)
EMBO J.
17,
1371-1384
12.
Kishida, S.,
Yamamoto, H.,
Ikeda, S.,
Kishida, M.,
Sakamoto, I.,
Koyama, S.,
and Kikuchi, A.
(1998)
J. Biol. Chem.
273,
10823-10826
13.
Sakanaka, C.,
Weiss, J. B.,
and Williams, L. T.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
3020-3023
14.
Nakamura, T.,
Hamada, F.,
Ishidate, T.,
Anai, K.,
Kawahara, K.,
Toyoshima, K.,
and Akiyama, T.
(1998)
Genes Cells
3,
395-403
15.
Orford, K.,
Crockett, C.,
Jensen, J. P.,
Weissman, A. M.,
and Byers, S. W.
(1997)
J. Biol. Chem.
272,
24735-24838
16.
Aberle, H.,
Bauer, A.,
Stappert, J.,
Kispert, A.,
and Kemler, R.
(1997)
EMBO J.
16,
3797-3804
17.
Munemitsu, S.,
Albert, I.,
Rubinfeld, B.,
and Polakis, P.
(1996)
Mol. Cell. Biol.
16,
4088-4094
18.
Winston, J. T.,
Strack, P.,
Beer-Romero, P.,
Chu, C. Y.,
Elledge, S. J.,
and Harper, J. W.
(1999)
Genes Dev.
13,
270-283
19.
Hart, M.,
Concordet, J. P.,
Lassot, I.,
Albert, I.,
del los Santos, R.,
Durand, H.,
Perret, C.,
Rubinfeld, B.,
Margottin, F.,
Benarous, R.,
and Polakis, P.
(1999)
Curr. Biol.
9,
207-210
20.
Latres, E.,
Chiaur, D. S.,
and Pagano, M.
(1999)
Oncogene
18,
849-854
21.
He, T. C.,
Sparks, A. B.,
Rago, C.,
Hermeking, H.,
Zawel, L.,
da Costa, L. T.,
Morin, P. J.,
Vogelstein, B.,
and Kinzler, K. W.
(1998)
Science
281,
1509-1512
22.
Tetsu, O.,
and McCormick, F.
(1999)
Nature
398,
422-426
23.
Kinzler, K. W.,
and Vogelstein, B.
(1996)
Cell
87,
159-170
24.
Rubinfeld, B.,
Robbins, P.,
El-Gamil, M.,
Albert, I.,
Porfiri, E.,
and Polakis, P.
(1997)
Science
275,
1790-1792
25.
de La Coste, A.,
Romagnolo, B.,
Billuart, P.,
Renard, C. A.,
Buendia, M. A.,
Soubrane, O.,
Fabre, M.,
Chelly, J.,
Beldjord, C.,
Kahn, A.,
and Perret, C.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8847-8851
26.
Zurawel, R. H.,
Chiappa, S. A.,
Allen, C.,
and Raffel, C.
(1998)
Cancer Res.
58,
896-899
27.
Ilyas, M.,
Tomlinson, I. P.,
Rowan, A.,
Pignatelli, M.,
and Bodmer, W. F.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10330-10334
28.
Chan, E. F.,
Gat, U.,
McNiff, J. M.,
and Fuchs, E.
(1999)
Nat. Genet.
21,
410-413
29.
Morin, P. J.,
Sparks, A. B.,
Korinek, V.,
Barker, N.,
Clevers, H.,
Vogelstein, B.,
and Kinzler, K. W.
(1997)
Science
275,
1787-1790
30.
Sparks, A. B.,
Morin, P. J.,
Vogelstein, B.,
and Kinzler, K. W.
(1998)
Cancer Res.
58,
1130-1134
31.
Kao, K. R.,
and Elinson, R. P.
(1998)
Biol. Cell
90,
585-589
32.
Sokol, S.,
Christian, J. L.,
Moon, R. T.,
and Melton, D. A.
(1991)
Cell
67,
741-752
33.
Pierce, S. B.,
and Kimelman, D.
(1995)
Development
121,
755-765
34.
He, X.,
Saint-Jeannet, J. P.,
Woodgett, J. R.,
Varmus, H. E.,
and Dawid, I. B.
(1995)
Nature
374,
617-622
35.
Funayama, N.,
Fagotto, F.,
McCrea, P.,
and Gumbiner, B. M.
(1995)
J. Cell Biol.
128,
959-968
36.
Van Lookeren Campagne, M. M.,
Wang, M.,
Spek, W.,
Peters, D.,
and Schaap, P.
(1988)
Dev. Genet.
9,
589-596
37.
Cheng, K.,
Creacy, S.,
and Larner, J.
(1983)
Mol. Cell. Biochem.
56,
183-189
38.
Berridge, M. J.,
Downes, C. P.,
and Hanley, M. R.
(1989)
Cell
59,
411-419
39.
Klein, P. S.,
and Melton, D. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8455-8459
40.
Stambolic, V.,
Ruel, L.,
and Woodgett, J. R.
(1996)
Curr. Biol.
6,
1664-1668
41.
Hedgepeth, C. M.,
Conrad, L. J.,
Zhang, J.,
Huang, H. C.,
Lee, V. M.,
and Klein, P. S.
(1997)
Dev. Biol.
185,
82-91
42.
Woodgett, J. R.
(1994)
Semin. Cancer Biol.
5,
269-275
43.
Dominguez, I.,
Itoh, K.,
and Sokol, S. Y.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8498-8502
44.
Siegfried, E.,
Chou, T. B.,
and Perrimon, N.
(1992)
Cell
71,
1167-1179
45.
Harwood, A. J.,
Plyte, S. E.,
Woodgett, J.,
Strutt, H.,
and Kay, R. R.
(1995)
Cell
80,
139-148
46.
Embi, N.,
Rylatt, D. B.,
and Cohen, P.
(1980)
Eur. J. Biochem.
107,
519-527
47.
Cohen, P.,
Yellowlees, D.,
Aitken, A.,
Donella-Deana, A.,
Hemmings, B. A.,
and Parker, P. J.
(1982)
Eur. J. Biochem.
124,
21-35
48.
Woodgett, J. R.
(1990)
EMBO J.
9,
2431-2438
49.
Cross, D. A.,
Alessi, D. R.,
Cohen, P.,
Andjelkovich, M.,
and Hemmings, B. A.
(1995)
Nature
378,
785-789
50.
Cook, D.,
Fry, M. J.,
Hughes, K.,
Sumathipala, R.,
Woodgett, J. R.,
and Dale, T. C.
(1996)
EMBO J.
15,
4526-4536
51.
Goode, N.,
Hughes, K.,
Woodgett, J. R.,
and Parker, P. J.
(1992)
J. Biol. Chem.
267,
16878-16882
52.
Bradley, R. S.,
and Brown, A. M.
(1995)
Mol. Cell. Biol.
15,
4616-4622
53.
Jue, S. F.,
Bradley, R. S.,
Rudnicki, J. A.,
Varmus, H. E.,
and Brown, A. M.
(1992)
Mol. Cell. Biol.
12,
321-328
54.
Korinek, V.,
Barker, N.,
Morin, P. J.,
van Wichen, D.,
de Weger, R.,
Kinzler, K. W.,
Vogelstein, B.,
and Clevers, H.
(1997)
Science
275,
1784-1787
55.
Cazaubon, S. M.,
and Parker, P. J.
(1993)
J. Biol. Chem.
268,
17559-17563
56.
Shimizu, H.,
Julius, M. A.,
Giarre, M.,
Zheng, Z.,
Brown, A. M.,
and Kitajewski, J.
(1997)
Cell Growth Differ.
8,
1349-1358
57.
Welsh, G. I.,
and Proud, C. G.
(1993)
Biochem. J.
294,
625-629
58.
Cohen, P.,
Alessi, D. R.,
and Cross, D. A.
(1997)
FEBS Lett.
410,
3-10
59.
Marte, B. M.,
Rodriguez-Viciana, P.,
Wennstrom, S.,
Warne, P. H.,
and Downward, J.
(1997)
Curr. Biol.
7,
63-70
60.
Katz, M. E.,
and McCormick, F.
(1997)
Curr. Opin. Genet. Dev.
7,
75-79
61.
McCormick, F.
(1995)
Mol. Reprod. Dev.
42,
500-506
62.
Peifer, M.,
Sweeton, D.,
Casey, M.,
and Wieschaus, E.
(1994)
Development
120,
369-380
63.
Papkoff, J.,
Rubinfeld, B.,
Schryver, B.,
and Polakis, P.
(1996)
Mol. Cell. Biol.
16,
2128-2134
64.
Welsh, G. I.,
Foulstone, E. J.,
Young, S. W.,
Tavare, J. M.,
and Proud, C. G.
(1994)
Biochem. J.
303,
15-20
65.
Cross, D. A.,
Alessi, D. R.,
Vandenheede, J. R.,
McDowell, H. E.,
Hundal, H. S.,
and Cohen, P.
(1994)
Biochem. J.
303,
21-26
66.
Sutherland, C.,
Leighton, I. A.,
and Cohen, P.
(1993)
Biochem. J.
296,
15-19
67.
Stambolic, V.,
and Woodgett, J. R.
(1994)
Biochem. J.
303,
701-704
68.
Shaw, M.,
Cohen, P.,
and Alessi, D. R.
(1997)
FEBS Lett.
416,
307-311
69.
Cui, H.,
Meng, Y.,
and Bulleit, R. F.
(1998)
Brain Res. Dev. Brain Res.
111,
177-188
70.
Hers, I.,
Tavare, J. M.,
and Denton, R. M.
(1999)
FEBS Lett.
460,
433-436
71.
Murray, N. R.,
Davidson, L. A.,
Chapkin, R. S.,
Clay Gustafson, W.,
Schattenberg, D. G.,
and Fields, A. P.
(1999)
J. Cell Biol.
145,
699-711
72.
Sheldahl, L. C.,
Park, M.,
Malbon, C. C.,
and Moon, R. T.
(1999)
Curr. Biol.
9,
695-698
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Kang, C. N. Bennett, I. Gerin, L. A. Rapp, K. D. Hankenson, and O. A. MacDougald Wnt Signaling Stimulates Osteoblastogenesis of Mesenchymal Precursors by Suppressing CCAAT/Enhancer-binding Protein {alpha} and Peroxisome Proliferator-activated Receptor {gamma} J. Biol. Chem., May 11, 2007; 282(19): 14515 - 14524. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. He, T. Sheng, A. A. Stelter, C. Li, X. Zhang, M. Sinha, B. A. Luxon, and J. Xie Suppressing Wnt Signaling by the Hedgehog Pathway through sFRP-1 J. Biol. Chem., November 24, 2006; 281(47): 35598 - 35602. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu, S. Thurig, O. Mohamed, D. Dufort, and V. A. Wallace Mapping Canonical Wnt Signaling in the Developing and Adult Retina Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 5088 - 5097. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Abramova, T. V. Pospelova, F. P. Nikulenkov, C. M. Hollander, A. J. Fornace Jr., and V. A. Pospelov G1/S Arrest Induced by Histone Deacetylase Inhibitor Sodium Butyrate in E1A + Ras-transformed Cells Is Mediated through Down-regulation of E2F Activity and Stabilization of beta-Catenin J. Biol. Chem., July 28, 2006; 281(30): 21040 - 21051. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-M. Xu, Y.-Q. Zhou, and M.-H. Wang Mechanisms of Cytoplasmic {beta}-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase J. Biol. Chem., July 1, 2005; 280(26): 25087 - 25094. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yang, W. W. Zhong, N. Srivastava, A. Slavin, J. Yang, T. Hoey, and S. An G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway PNAS, April 26, 2005; 102(17): 6027 - 6032. [Abstract] [Full Text] [PDF] |
||||